share_log

Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target

Benzinga Real-time News ·  Feb 21, 2023 08:44

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment